Claims for Patent: 6,548,529

Summary for Patent: 6,548,529

Title:	Heterocyclic containing biphenyl aP2 inhibitors and method
Abstract:	aP2 inhibiting compounds are provided having the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2## are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
Inventor(s):	Robl; Jeffrey A. (Newtown, PA), Sulsky; Richard B. (West Trenton, NJ), Magnin; David R. (Hamilton, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	09/519,079
Patent Claims:	1. A compound having the structure ##STR299## wherein R.sup.1 and R.sup.2 are the same or different and are independently selected from hydrogen, alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heteroarylalkyl, aralkyl, cycloheteroalkyl or cycloheteroalkylalkyl; R.sup.3 is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, alkylcarbonyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkenylalkyl, haloalkyl, polyhaloalkyl, cyano, nitro, hydroxy, amino, alkanoyl, alkylthio, alkylsulfonyl, alkoxycarbonyl, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyloxy, alkylaminosulfonyl, alkylamino, dialkylamino, all optionally substituted through available carbon atoms with 1, 2, 3, 4 or 5 groups selected from hydrogen, halo, alkyl, polyhaloalkyl, alkoxy, haloalkoxy, polyhaloalkoxy, alkoxycarbonyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, hydroxy, hydroxyalkyl, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, alkylcarbonyl, acyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino, alkylsulfonyl, aminosulfinyl, aminosulfonyl, alkylsulfinyl, sulfonamido or sulfonyl; R.sup.4 is selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, polycycloalkylalkyl, cycloalkenyl, cycloalkynyl, alkylcarbonyl, arylcarbonyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkenylalkyl, polycycloalkenyl, polycycloalkenylalkyl, polycycloalkynyl, polycycloalkynylalkyl, haloalkyl, polyhaloalkyl, cyano, nitro, hydroxy, amino, alkanoyl, aroyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, alkoxycarbonyloxy, alkylaminosulfonyl, arylaminosulfonyl, alkylamino, dialkylamino, all optionally substituted through available carbon atoms with 1, 2, 3, 4 or 5 groups selected from hydrogen, halo, alkyl, haloalkyl, polyhaloalkyl, alkoxy, haloalkoxy, polyhaloalkoxy, alkoxycarbonyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, arylcycloalkyl, arylalkenyl, arylalkynyl, aryloxy, aryloxyalkyl, arylalkoxy, arylazo, heteroaryloxo, heteroarylalkyl, heteroarylalkenyl, heteroaryloxy, hydroxy, hydroxyalkyl, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkylcarbonyl, arylcarbonyl, acyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, alkylsulfonyl, aminosulfinyl, aminosulfonyl, arylsulfonylamino, heteroarylcarbonylamino, heteroarylsulfinyl, heteroarylthio, heteroarylsulfonyl, alkylsulfinyl, sulfonamido or sulfonyl; X is a bond or a linker group selected from (CH.sub.2).sub.n, O(CH.sub.2).sub.n, S(CH.sub.2).sub.n, cycloalkylene, N(R.sup.5) (CH.sub.2).sub.n, NHCO, or CH.dbd.CH where n=0-5 and R.sup.5 is hydrogen, alkyl, or alkanoyl; Z is CO.sub.2 H or tetrazole of the formula ##STR300## or its tautomer; and the group ##STR301## is pyrazole which may further be optionally substituted with alkyl, alkenyl, hydroxyalkyl, keto, carboxyalkyl, carboxy, cycloalkyl, alkoxy, formyl, alkanoyl, alkoxyalkyl or alkoxycarbonyl, including all stereoisomers thereof; or a pharmaceutically acceptable salt thereof, or a prodrug ester thereof; with the proviso that n.noteq.when Z is CO.sub.2 H and X is O(CH.sub.2).sub.n, S(CH.sub.2).sub.n or N(R.sup.5) (CH.sub.2).sub.n). 2. The compound as defined in claim 1 wherein R.sup.3 and R.sup.4 are the same or different and are independently selected from hydrogen, halogen, alkyl, alkoxy, alkylthio, haloalkyl, CF.sub.3, cyano, hydroxy, or nitro. 3. The compound as defined in claim 1 wherein ##STR302## is ##STR303## where R.sup.8 is selected from H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, and R.sup.9 is selected from H, alkyl, alkenyl, formyl, CO.sub.2 (lower alkyl), hydroxyalkyl, alkoxyalkyl, CO(alkyl), carboxyalkyl, haloalkyl, alkenyl or cycloalkyl. 4. The compound as defined in claim 1 wherein R.sup.1 and R.sup.2 are the same or different and are independently selected from aryl, cycloalkyl, heteroaryl or hydrogen. 5. The compound as defined in claim 1 wherein R.sup.1 and R.sup.2 are the same or different and are independently selected from phenyl, cyclohexyl, hydrogen or pyrido. 6. The compound as defined in claim 1 wherein R.sup.3 and R.sup.4 are the same or different and are independently selected from hydrogen, alkyl or halogen. 7. The compound as defined in claim 1 wherein --X-- Z is ##STR304## 8. The compound as defined in claim 1 wherein ##STR305## is ##STR306## where R.sup.8 is H, lower alkyl, fluoroalkyl, or alkoxyalkyl, and R.sup.9 is H, lower alkyl, fluoroalkyl, alkoxy or hydroxyalkyl; R.sup.1 and R.sup.2 are the same or different and are independently selected from phenyl or substituted phenyl; R.sup.3 and R.sup.4 are the same or different are independently selected from H, halo, alkyl or alkoxy; X is OCH.sub.2, NHCH.sub.2, CH.sub.2 or CH.sub.2 CH.sub.2 ; and Z is CO.sub.2 H or tetrazole. 9. The compound as defined in claim 1 where ##STR307## is ##STR308## where R.sup.9 is H, lower alkyl, fluoroalkyl, or alkoxy; R.sup.1 and R.sup.2 are each phenyl; R.sup.3 and R.sup.4 are each H; X is OCH.sub.2, CH.sub.2 or NHCH.sub.2 ; and Z is CO.sub.2 H or tetrazole. 10. The compound as defined in claim 1 wherein ##STR309## R.sup.3 is H R.sup.4 is H and --X--Z is ##STR310## 11. The compound as defined in claim 1 which is ##STR311## ##STR312## 12. The compound as defined in claim 1 which is ##STR313## 13. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor. 14. A pharmaceutical combination comprising an aP2 inhibitor compound as defined in claim 1 and an antidiabetic agent other than an aP2 inhibitor, an anti-obesity agent, a lipid-lowering agent, an anti-hypertensive agent, an anti-platelet agent and/or an anti-infective agent. 15. The pharmaceutical combination as defined in claim 14 comprising said aP2 inhibitor compound and an antidiabetic agent. 16. The combination as defined in claim 15 wherein the antidiabetic agent is 1, 2, 3 or more of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPAR .gamma. agonist, a PPAR .alpha./.gamma. dual agonist, an SGLT2 inhibitor, a DP4 inhibitor, an insulin sensitizer, a glucagon-like peptide-1 (GLP-1), insulin and/or a meglitinide. 17. The combination as defined in claim 16 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, G1-262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-H039242, GW-409544, KRP297, AC2993, LY315902, and/or NVP-DPP-728A. 18. The combination as defined in claim 15 wherein the compound is present in a weight ratio to the antidiabetic agent within the range from about 0.01 to about 100:1. 19. The combination as defined in claim 14 wherein the anti obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor beta compound, and/or an anorectic agent. 20. The combination as defined in claim 19 wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol. 21. The combination as defined in claim 14 wherein the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor. 22. The combination as defined in claim 21 wherein the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nisvastatin, visastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, and/or LY295427. 23. The combination as defined in claim 21 wherein the aP2 inhibitor is present in a weight ratio to the lipid-lowering agent within the range from about 0.01 to about 100:1. 24. The combination as defined in claim 14 wherein the anti-hypertensive agent is an ACE inhibitor, a vasopeptidase inhibitor, an angiotensin-II antagonist, a calcium-channel blocker, an alpha-blocker, a beta-blocker, a potassium channel opener, a centrally acting alpha agonist, and/or a diuretic. 25. The combination as defined in claim 24 wherein the anti-hypertensive agent is omapatrilat, [S-(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimet hyl-7-oxo-1H-azepine-1-acetic acid, lisinopril, enalapril, quinapril, benazepril, fosinopril, ramipril, captopril, enalaprilat, moexipril, trandolapril, perindopril, losartan, valsartan, irbesartan, candesartan, telmisartan, amlodipine, diltiazem, nifedipine, verapamil, felodipine, nisoldipine, isradipine, nicardipine, terazosin, doxazosin, prazosin, nadolol, propranolol, metoprolol, atenolol, carvedilol, sotalol, hydrochlorthiazide, torasemide, furosemide, spironolactone, indapamide, clonidine and/or guanfacine. 26. The combination as defined in claim 14 wherein the anti-platelet agent is aspirin, clopidogrel, ticlopidine, abciximab, tirofiban, eptifibatide, anagrelide and/or dipyridamole. 27. The combination as defined in claim 14 wherein the anti-infective is azithromycin, gatifoxacin, ciprofloxacin, levofloxacin, or trovafloxacin.

Details for Patent 6,548,529

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2019-04-05